Improving anxiety-induced insomnia with lavender oil29 Aug 2019
New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.
Pharmaceutical-quality lavender oil has a significant anxiolytic (anxiety relieving) effect and improves insomnia when taken orally as a daily capsule, new data shows.
Disturbed sleep is a prevalent symptom in anxiety disorders and a key diagnosis criterion for subthreshold and generalised anxiety disorders (GAD). It is estimated that more than two thirds of patients with GAD suffer from insomnia, with even higher rates amongst the elderly, causing a detrimental effect on patients’ daily living skills and quality of life. In 80% of patients with diagnosed anxiety disorders, symptoms of insomnia appear simultaneously with anxiety symptoms(5) highlighting the importance of targeting insomnia in the treatment of anxiety.
Pharmacological anxiety treatments such as benzodiazepines carry a sedating effect. Although some patients may see a short-term improvement in sleep, common side effects of benzodiazepine use include daytime drowsiness and rebound insomnia – further intensifying sleep disturbances. Benzodiazepines can also cause a physical dependence and withdrawal reaction when taken for longer than the recommended 4 weeks, a common withdrawal symptom is insomnia making it hard for patients to break the anxiety-insomnia cycle.
A mediation analysis by researchers from the Universities of Zurich and Basel published this month in the Journal of Psychiatric Research, found that 98.4% of patients saw an improvement in anxiety-related sleep disturbances when taking a daily capsule of pharmaceutical quality lavender oil vs placebo. The results indicate that pharmaceutical quality lavender oil exerts a secondary sleep improving effect almost exclusively through its anxiety-relieving action rather than by sedation(.
Pharmaceutical quality lavender oil capsules are shown to decrease excessive neurotransmitter activity, reducing overstimulation and hyperactivity of the nervous response - improving symptoms of mild anxiety. More than 15 clinical trials show that a daily lavender oil capsule can be AS EFFECTIVE as commonly used anti-anxiety medication, including the benzodiazepine lorazepam prescribed in GAD without the risk of sedation, dependency or withdrawal.
Professor of Psychiatry, Professor Hans-Peter Volz comments: ‘’This is a positive development for anxiety. Research demonstrates that the lavender oil capsules reduce both physical and psychological symptoms of anxiety (including sleep disturbances), without issues such as sedation, addiction or withdrawal. Lavender oil capsules provide a promising alternative treatment option to prescription drugs for subthreshold anxiety sufferers.”
The anxiety-relieving effects of uniquely prepared, pharmaceutical quality lavender oil are available only in Kalms Lavender One-A-Day Capsules.
Nicky Lidbetter, CEO of Anxiety UK states: ‘’Anxiety is one of the most prevalent mental health conditions in the UK - one in five people report feeling anxious a lot or all of the time; and more than 45 million working days have been lost due to anxiety (combined with depression and stress) in the past three years. We welcome a range of treatment and support options, including the Kalms Lavender One-a-Day capsule and other non-prescription options such as talking therapies.”
Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD
21 Feb 2020
Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.Read more
Catalent to manufacture first-in-class mAb targeting solid tumours
11 Feb 2020
ZM008 could have potential benefits for the treatment of prostate cancer.Read more
BD completes clinical trial for its wearable injector
11 Feb 2020
The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.Read more
New Velesco Pharma clinical manufacturing facility begins operations
5 Feb 2020
The facility will triple the company’s cGMP clinical trial manufacturing capacity.Read more
Inovio and Beijing Advaccine to advance vaccine against Coronavirus
30 Jan 2020
Agreement will facilitate clinical trial translations in China.Read more
First human trial of monoclonal antibody to prevent malaria opens
28 Jan 2020
If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.Read more
Thermo launches next-generation, compressor-free plate sealer
28 Jan 2020
Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.Read more
Merck invests in biotech development facility in Switzerland
27 Jan 2020
€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.Read more
Grey Wolf Therapeutics secures funding for cancer therapies development
21 Jan 2020
The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.Read more
Diabetes diagnosis - now a matter of sweat and tears?
21 Jan 2020
No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation